PPARG and neoplasm: In addition, rosiglitazone, another agonist of PPARγ, was found to impede colorectal cell proliferation by activating PTEN (a tumor suppressor) and regulating the expression of phosphatidylinositol 3-kinase (PI3-kinase) [23].